• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Protozoal Infection - Pipeline Review, H2 2012 Product Image

Protozoal Infection - Pipeline Review, H2 2012

  • Published: October 2012
  • 405 pages
  • Global Markets Direct

Protozoal Infection – Pipeline Review, H2 2012

Summary

Global Markets Direct’s, 'Protozoal Infection - Pipeline Review, H2 2012', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Protozoal Infection, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Protozoal Infection. Protozoal Infection - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Protozoal Infection.
- A review of the Protozoal Infection products under development by companies and universities/research READ MORE >

2
List of Tables 23
List of Figures 25
Introduction 26
REPORT COVERAGE 26
Protozoal Infection Overview 27
Therapeutics Development 28
An Overview of Pipeline Products for Protozoal Infection 28
Protozoal Infection Therapeutics under Development by Companies 30
Protozoal Infection Therapeutics under Investigation by Universities/Institutes 36
Late Stage Products 41
Comparative Analysis 41
Mid Clinical Stage Products 42
Comparative Analysis 42
Early Clinical Stage Products 43
Comparative Analysis 43
Discovery and Pre-Clinical Stage Products 44
Comparative Analysis 44
Protozoal Infection Therapeutics – Products under Development by Companies 45
Protozoal Infection Therapeutics – Products under Investigation by Universities/Institutes 50
Companies Involved in Protozoal Infection Therapeutics Development 58
Sanofi-Aventis 58
GlaxoSmithKline plc 59
Inovio Biomedical Corporation 60
GenVec, Inc. 61
Merck & Co., Inc. 62
Eastland Medical Systems Limited 63
Novartis AG 64
Actelion Ltd 65
Eisai Co., Ltd. 66
Pfizer Inc. 67
Ranbaxy Laboratories Limited 68
Aduro BioTech 69
CEL-SCI Corporation 70
Crucell N.V. 71
Merck KGaA 72
iCo Therapeutics Inc. 73
BioDiem Ltd 74
Mymetics Corporation 75
Cleveland BioLabs, Inc. 76
Patrys Limited 77
Alnylam Pharmaceuticals, Inc 78
IPCA Laboratories Limited 79
Lipoxen PLC 80
MOLOGEN AG 81
Raptor Pharmaceuticals Corp. 82
PolyMedix, Inc. 83
Affitech A/S 84
Colby Pharmaceutical Company 85
Avanti Therapeutics 86
Bharat Biotech International Limited 87
Jenrin Discovery, Inc. 88
Mucosis B.V. 89
Snowdon Inc. 90
Dafra Pharma International Ltd. 91
Anacor Pharmaceuticals, Inc. 92
Telormedix SA 93
Dilafor AB 94
Okairos 95
aRigen Pharmaceuticals, Inc. 96
Phage Biotechnology Corporation 97
Sanaria Inc. 98
NovaLead Pharma Pvt. Ltd. 99
ImmunoVaccine Technologies Inc. 100
Acetylon Pharmaceuticals, Inc. 101
Etubics Corporation 102
iBio, Inc. 103
PepTcell Limited 104
Genocea Biosciences, Inc. 105
PALUMED S.A. 106
Sigma-Tau Pharmaceuticals, Inc. 107
PATH Malaria Vaccine Initiative 108
Selecta Biosciences, Inc. 109
Pfenex Inc. 110
VLP Biotech, Inc. 111
Centro Internacional de Entrenamiento e Investigaciones Medicas 112
Jomaa Pharma GmbH 113
Protozoal Infection – Therapeutics Assessment 114
Assessment by Monotherapy Products 114
Assessment by Combination Products 115
Assessment by Route of Administration 116
Assessment by Molecule Type 119
Drug Profiles 122
SAR-97276 - Drug Profile 122
Product Description 122
Mechanism of Action 122
R&D Progress 122
ferroquine - Drug Profile 123
Product Description 123
Mechanism of Action 123
R&D Progress 123
Malaria Vaccine - Drug Profile 124
Product Description 124
Mechanism of Action 124
R&D Progress 124
tafenoquine - Drug Profile 126
Product Description 126
Mechanism of Action 126
R&D Progress 126
PMX-30024 - Drug Profile 128
Product Description 128
Mechanism of Action 128
R&D Progress 128
ravuconazole - Drug Profile 129
Product Description 129
Mechanism of Action 129
R&D Progress 129
artemether - Drug Profile 131
Product Description 131
Mechanism of Action 131
R&D Progress 131
CEL-1000 - Drug Profile 132
Product Description 132
Mechanism of Action 132
R&D Progress 132
artesunate - Drug Profile 135
Product Description 135
Mechanism of Action 135
R&D Progress 135
Drug targeting dihydroorotate dehydrogenase - Drug Profile 148
Product Description 148
Mechanism of Action 148
R&D Progress 148
Synriam - Drug Profile 149
Product Description 149
Mechanism of Action 149
R&D Progress 149
Drug targeting dihydroorotate dehydrogenase - Drug Profile 150
Product Description 150
Mechanism of Action 150
R&D Progress 150
novel liver stage antimalarials - Drug Profile 151
Product Description 151
Mechanism of Action 151
R&D Progress 151
JD-3000 Series - Drug Profile 152
Product Description 152
Mechanism of Action 152
R&D Progress 152
CST-102 - Drug Profile 153
Product Description 153
Mechanism of Action 153
R&D Progress 153
Miltefosine + Liposomal Amphotericin B - Drug Profile 172
Product Description 172
Mechanism of Action 172
R&D Progress 172
Amodiaquine + Artesunate - Drug Profile 173
Product Description 173
Mechanism of Action 173
R&D Progress 173
Coartem - Drug Profile 174
Product Description 174
Mechanism of Action 174
R&D Progress 174
Amodiaquine + Artesunate - Drug Profile 176
Product Description 176
Mechanism of Action 176
R&D Progress 176
Artemether + Lumefantrine - Drug Profile 177
Product Description 177
Mechanism of Action 177
R&D Progress 177
Amodiaquine + Sulfadoxine + Pyrimethamine - Drug Profile 179
Product Description 179
Mechanism of Action 179
R&D Progress 179
AmBisome + Miltefosine - Drug Profile 181
Product Description 181
Mechanism of Action 181
R&D Progress 181
Artekin - Drug Profile 183
Product Description 183
Mechanism of Action 183
R&D Progress 183
amphotericin B - Drug Profile 185
Product Description 185
Mechanism of Action 185
R&D Progress 185
Liposomal Amphotericin B + Miltefosine - Drug Profile 186
Product Description 186
Mechanism of Action 186
R&D Progress 186
Liposomal Amphotericin B + Paromomycin Sulfate - Drug Profile 188
Product Description 188
Mechanism of Action 188
R&D Progress 188
Paromomycin Sulfate + Miltefosine - Drug Profile 190
Product Description 190
Mechanism of Action 190
R&D Progress 190
amphotericin B - Drug Profile 241
Product Description 241
Mechanism of Action 241
R&D Progress 241
Dihydroartemisinin + Piperaquine - Drug Profile 245
Product Description 245
Mechanism of Action 245
R&D Progress 245
GMCSF + Antimony - Drug Profile 247
Product Description 247
Mechanism of Action 247
R&D Progress 247
Pf-27 LSP - Drug Profile 314
Product Description 314
Mechanism of Action 314
R&D Progress 314
Mefloquine + Artesunate - Drug Profile 315
Product Description 315
Mechanism of Action 315
R&D Progress 315
AN-3661 - Drug Profile 316
Product Description 316
Mechanism of Action 316
R&D Progress 316
Lm Malaria - Drug Profile 318
Product Description 318
Mechanism of Action 318
R&D Progress 318
Vaccine Adjuvant - Drug Profile 370
Product Description 370
Mechanism of Action 370
R&D Progress 370
Malaria Vaccine - Drug Profile 371
Product Description 371
Mechanism of Action 371
R&D Progress 371
Protozoal Infection Therapeutics – Drug Profile Updates 372
Protozoal Infection Therapeutics – Discontinued Products 381
Protozoal Infection Therapeutics - Dormant Products 384
Protozoal Infection – Product Development Milestones 397
Featured News & Press Releases 397
Jun 13, 2012: Sanaria And Institute For Bioscience And Biotechnology Research Receive $3m NIH Phase II Small Business Innovation Research Grant 397
May 03, 2012: BioDiem Receives New US Patent Covering Antimicrobial Compound BDM-I 397
Apr 25, 2012: Ranbaxy Launches Synriam In India 398
Mar 12, 2012: Anacor Announces Commencement Of Phase I Clinical Trials Of Boron-Based Compound For Sleeping Sickness 398
Mar 12, 2012: DNDi Receives €2m Strategic Translation Award From Wellcome Trust To Develop New Drug Against Chagas Disease 399
Feb 27, 2012: Modified Bone Drug Kills Malaria Parasite In Mice, Study Reports 400
Feb 22, 2012: IDRI Launches First Clinical Trial For New Vaccine To Treat Leishmaniasis 400
Feb 17, 2012: European Medicines Agency Recommends New Anti-Malaria Treatment For Use Outside EU 401
Feb 02, 2012: University Of Dundee Researchers Identify Potential New Treatment For Leishmaniasis 402
Jan 19, 2012: NIH Tests PfSPZ Vaccine Made From Weakened Malaria Parasites In Phase I Trial 403
Appendix 404
Methodology 404
Coverage 404
Secondary Research 404
Primary Research 404
Expert Panel Validation 404
Contact Us 405
Disclaimer 405

List of Tables
Number of Products Under Development for Protozoal Infection, H2 2012 28
Products under Development for Protozoal Infection – Comparative Analysis, H2 2012 29
Number of Products under Development by Companies, H2 2012 31
Number of Products under Development by Companies, H2 2012 (Contd..1) 32
Number of Products under Development by Companies, H2 2012 (Contd..2) 33
Number of Products under Development by Companies, H2 2012 (Contd..3) 34
Number of Products under Development by Companies, H2 2012 (Contd..4) 35
Number of Products under Investigation by Universities/Institutes, H2 2012 37
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 38
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 39
Number of Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 40
Comparative Analysis by Late Stage Development, H2 2012 41
Comparative Analysis by Mid Clinical Stage Development, H2 2012 42
Comparative Analysis by Early Clinical Stage Development, H2 2012 43
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2012 44
Products under Development by Companies, H2 2012 45
Products under Development by Companies, H2 2012 (Contd..1) 46
Products under Development by Companies, H2 2012 (Contd..2) 47
Products under Development by Companies, H2 2012 (Contd..3) 48
Products under Development by Companies, H2 2012 (Contd..4) 49
Products under Investigation by Universities/Institutes, H2 2012 50
Products under Investigation by Universities/Institutes, H2 2012 (Contd..1) 51
Products under Investigation by Universities/Institutes, H2 2012 (Contd..2) 52
Products under Investigation by Universities/Institutes, H2 2012 (Contd..3) 53
Products under Investigation by Universities/Institutes, H2 2012 (Contd..4) 54
Products under Investigation by Universities/Institutes, H2 2012 (Contd..5) 55
Products under Investigation by Universities/Institutes, H2 2012 (Contd..6) 56
Products under Investigation by Universities/Institutes, H2 2012 (Contd..7) 57
Sanofi-Aventis, H2 2012 58
GlaxoSmithKline plc, H2 2012 59
Inovio Biomedical Corporation, H2 2012 60
GenVec, Inc., H2 2012 61
Merck & Co., Inc., H2 2012 62
Eastland Medical Systems Limited, H2 2012 63
Novartis AG, H2 2012 64
Actelion Ltd, H2 2012 65
Eisai Co., Ltd., H2 2012 66
Pfizer Inc., H2 2012 67
Ranbaxy Laboratories Limited, H2 2012 68
Aduro BioTech, H2 2012 69
CEL-SCI Corporation, H2 2012 70
Crucell N.V., H2 2012 71
Merck KGaA, H2 2012 72
iCo Therapeutics Inc., H2 2012 73
BioDiem Ltd, H2 2012 74
Mymetics Corporation, H2 2012 75
Cleveland BioLabs, Inc., H2 2012 76
Patrys Limited, H2 2012 77
Alnylam Pharmaceuticals, Inc, H2 2012 78
IPCA Laboratories Limited, H2 2012 79
Lipoxen PLC, H2 2012 80
MOLOGEN AG, H2 2012 81
Raptor Pharmaceuticals Corp., H2 2012 82
PolyMedix, Inc., H2 2012 83
Affitech A/S, H2 2012 84
Colby Pharmaceutical Company, H2 2012 85
Avanti Therapeutics, H2 2012 86
Bharat Biotech International Limited, H2 2012 87
Jenrin Discovery, Inc., H2 2012 88
Mucosis B.V., H2 2012 89
Snowdon Inc., H2 2012 90
Dafra Pharma International Ltd., H2 2012 91
Anacor Pharmaceuticals, Inc., H2 2012 92
Telormedix SA, H2 2012 93
Dilafor AB, H2 2012 94
Okairos, H2 2012 95
aRigen Pharmaceuticals, Inc., H2 2012 96
Phage Biotechnology Corporation, H2 2012 97
Sanaria Inc., H2 2012 98
NovaLead Pharma Pvt. Ltd., H2 2012 99
ImmunoVaccine Technologies Inc., H2 2012 100
Acetylon Pharmaceuticals, Inc., H2 2012 101
Etubics Corporation, H2 2012 102
iBio, Inc., H2 2012 103
PepTcell Limited, H2 2012 104
Genocea Biosciences, Inc., H2 2012 105
PALUMED S.A., H2 2012 106
Sigma-Tau Pharmaceuticals, Inc., H2 2012 107
PATH Malaria Vaccine Initiative, H2 2012 108
Selecta Biosciences, Inc., H2 2012 109
Pfenex Inc., H2 2012 110
VLP Biotech, Inc., H2 2012 111
Centro Internacional de Entrenamiento e Investigaciones Medicas, H2 2012 112
Jomaa Pharma GmbH, H2 2012 113
Assessment by Monotherapy Products, H2 2012 114
Assessment by Combination Products, H2 2012 115
Assessment by Stage and Route of Administration, H2 2012 118
Assessment by Stage and Molecule Type, H2 2012 121
Protozoal Infection Therapeutics – Drug Profile Updates 372
Protozoal Infection Therapeutics – Discontinued Products 381
Protozoal Infection Therapeutics – Discontinued Products (Contd..1) 382
Protozoal Infection Therapeutics – Discontinued Products (Contd..2) 383
Protozoal Infection Therapeutics – Dormant Products 384
Protozoal Infection Therapeutics – Dormant Products (Contd..1) 385
Protozoal Infection Therapeutics – Dormant Products (Contd..2) 386
Protozoal Infection Therapeutics – Dormant Products (Contd..3) 387
Protozoal Infection Therapeutics – Dormant Products (Contd..4) 388
Protozoal Infection Therapeutics – Dormant Products (Contd..5) 389
Protozoal Infection Therapeutics – Dormant Products (Contd..6) 390
Protozoal Infection Therapeutics – Dormant Products (Contd..7) 391
Protozoal Infection Therapeutics – Dormant Products (Contd..8) 392
Protozoal Infection Therapeutics – Dormant Products (Contd..9) 393
Protozoal Infection Therapeutics – Dormant Products (Contd..10) 394
Protozoal Infection Therapeutics – Dormant Products (Contd..11) 395
Protozoal Infection Therapeutics – Dormant Products (Contd..12) 396

List of Figures
Number of Products under Development for Protozoal Infection, H2 2012 28
Products under Development for Protozoal Infection – Comparative Analysis, H2 2012 29
Products under Development by Companies, H2 2012 30
Products under Investigation by Universities/Institutes, H2 2012 36
Late Stage Products, H2 2012 41
Mid Clinical Stage Products, H2 2012 42
Early Clinical Stage Products, H2 2012 43
Discovery and Pre-Clinical Stage Products, H2 2012 44
Assessment by Monotherapy Products, H2 2012 114
Assessment by Combination Products, H2 2012 115
Assessment by Route of Administration, H2 2012 116
Assessment by Stage and Route of Administration, H2 2012 117
Assessment by Molecule Type, H2 2012 119
Assessment by Stage and Molecule Type, H2 2012 120

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos